NCT00643045View on ClinicalTrials.gov

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

PHASE3CompletedINTERVENTIONAL
Enrollment

269

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

January 31, 2006

Study Completion Date

July 31, 2007

Conditions
Idiopathic Parkinson's Disease
Interventions
DRUG

Safinamide

DRUG

Safinamide

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Newron Pharmaceuticals SPA

INDUSTRY

NCT00643045 - Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist | Biotech Hunter | Biotech Hunter